|
||
|
Venture capital firms and funds in Europe 128 Venture Capital Group 3i Venture Capital Accuitive Medical Acer Venture Capital Act Venture Capital Ltd Adelaide Venture Capital Email ADS Ventures Boston Advantages Of Venture Capital Advent Venture Capital Agio Capital Alabama Venture Capital Alaska Venture Capital All Stages Venture Capital American Venture Capital Analysis Venture Capital Analyze Venture Capital Angel Capital Appraisal Venture Capital Arch Venture Capital Argentina Venture Capital Arizona Venture Capital Arkansas Venture Capital Arrowpath Venture Capital Assess Venture Capital Assessment Venture Capital Atlas Venture Capital ATV Venture Capital Aurora Fund Australia Venture Capital Austria Venture Capital Automotive Venture Capital AZ Venture Capital VCgate More Venture Capital Terms and Topics
-
BioRelix Announces $25.75 Million Series A Financing
June 11th, 2007 No comments
BioRelix, Inc., a biopharmaceutical company focused on the development of novel anti-infective agents, announced recently the completion of a $25.75 million Series A financing. The financing was led by CHL Medical Partners with participation by new investors New Leaf Venture Partners and Aisling Capital and existing investors Novartis Venture Fund, Elm Street Ventures and Alexandria Real Estate Equities. BioRelix expects to use the funds to build a portfolio of anti-infective product candidates based on novel patented bacterial RNA targets, termed RiboSwitches™, which were identified by the laboratory of BioRelix’ co-founder, Ronald Breaker, Ph.D., Howard Hughes Investigator and Henry Ford II Professor at Yale University.
“We are extremely pleased to have a prestigious group of investors who support the company’s strategy and approach to building a pipeline of anti-bacterial products,” stated Ronald W. Lennox, D. Phil., a partner with CHL Medical Partners and interim CEO. “We anticipate that the Series A financing will allow us to file an IND with at least one RiboSwitch class and advance other compounds targeting different RiboSwitch classes through late stage pre-clinical development. In the near term, we expect to have a CEO in place by early fall of this year.”
In connection with the Series A financing, Philippe Chambon, M.D., Ph.D., Managing Director of NLV Partners, Dov A. Goldstein, M.D., Principal of Aisling Capital, and Campbell Murray, M.D., Managing Director of Novartis Venture Fund, have been added to the BioRelix Board of Directors. Current directors of the company also include Ronald Lennox, D. Phil, Professor A. Donny Strosberg, Dr. Sci., of the Scripps Research Institute and William Wiesler, Ph.D., of Yale University.
Dr. Breaker commented, “BioRelix’ proprietary technology platform addresses the widespread and growing prevalence of resistant bacterial strains that are presenting in both the hospital and community settings. RiboSwitches constitute the first new major class of targets for anti-infective drug discovery in decades and in fact seem to underlie the activity of several compounds with known antibacterial activity. Our recent research has also demonstrated that RiboSwitches may have broad-spectrum activity against Gram-positive and Gram-negative bacteria. We are continuing to explore the mechanism of action of this class of targets, including the potential to reduce toxicity, as well as possible applications in anti-fungal therapy.”
For more information, please visit www.biorelix.com
Leave a reply
Latest Headlines:
Friday August 31, 2012
Zscaler Secures $38 Million Investment Round
Wednesday November 30, 2011
Health Care Solutions companies Infinity Pharmaceutics, NanoVobronix and Selventa raise funds.
Monday November 21, 2011
Panda Power opens $420 Million Fund for Solar and Natural Gas Projects
Thursday November 17, 2011
Better Place raises $200 Million for Electric Cars in the Series C of Funding
Wednesday November 16, 2011
Accel Partners raise $100 Million Big Data Fund to Invest in Hadoop, NoSQL and other Companies
Tuesday November 15, 2011
Skimlinks raises $4.5 Million to help Bloggers Increase their Gains
Monday November 14, 2011
Standing Cloud raises $3 Million to help New Cloud Providers grow Faster
Thursday November 10, 2011
Zillow acquires Diverse Solutions for $7.8 to help Real Estate Agents increase their Visibility